홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Sodium cyanoborohydride → 7-tert-Butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-2,3-dihydro-1H-quinazolin-4-one

HRID 1916071
인쇄

반응식

HRID 1916071 반응식
[C:1]([C:5]1[CH:14]=[C:13]2[C:8]([C:9](=[O:45])[N:10]([C:15]3[CH:20]=[CH:19][CH:18]=[C:17]([C:21]4[CH:26]=[C:25]([NH:27][C:28]5[CH:33]=[CH:32][C:31]([C:34]([N:36]6[CH2:41][CH2:40][O:39][CH2:38][CH2:37]6)=[O:35])=[CH:30][N:29]=5)[C:24](=[O:42])[N:23]([CH3:43])[N:22]=4)[C:16]=3[CH3:44])[CH:11]=[N:12]2)=[CH:7][CH:6]=1)([CH3:4])([CH3:3])[CH3:2].C([BH3-])#N.[Na+]>CO.Cl>[C:1]([C:5]1[CH:14]=[C:13]2[C:8]([C:9](=[O:45])[N:10]([C:15]3[CH:20]=[CH:19][CH:18]=[C:17]([C:21]4[CH:26]=[C:25]([NH:27][C:28]5[CH:33]=[CH:32][C:31]([C:34]([N:36]6[CH2:41][CH2:40][O:39][CH2:38][CH2:37]6)=[O:35])=[CH:30][N:29]=5)[C:24](=[O:42])[N:23]([CH3:43])[N:22]=4)[C:16]=3[CH3:44])[CH2:11][NH:12]2)=[CH:7][CH:6]=1)([CH3:4])([CH3:3])[CH3:2]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

5

반응물 2

HCID 5003444Sodium cyanoborohydrideHCID 252655857-tert-Butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-3H-quinazolin-4-one

생성물 1

HCID 445535587-tert-Butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-2,3-dihydro-1H-quinazolin-4-one수율 61.1%

시약·촉매·용매 2

HCID 313
Hydrochloric Acid
촉매
HCID 887Methanol용매2회

실험 절차

To a mixture of 7-tert-Butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-3H-quinazolin-4-one (11 mg, 0.018 mmol) and sodium cyanoborohydride (1.3 mg, 0.019 mmol) in 1 mL methanol was added 1 drop of 2M hydrochloric acid in methanol to bring the pH to 3. After stirring for 45 minutes, the resulting mixture was partitioned between ethylacetate and dilute aqueous NaHCO3. The ethylacetate layer was washed with brine, dried over anhydrous MgSO4, concentrated in vacuo, and purified by preparative TLC (5% MeOH/CH2Cl2) to yield 7-tert-Butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-2,3-dihydro-1H-quinazolin-4-one (6.5 mg, 0.011 mmol). MS (ESI) 608 (M+H)+.

후처리

  1. customthe resulting mixture was partitioned between ethylacetate and dilute aqueous NaHCO3
  2. washThe ethylacetate layer was washed with brine
  3. dry with materialdried over anhydrous MgSO4
  4. concentrationconcentrated in vacuo
  5. custompurified by preparative TLC (5% MeOH/CH2Cl2)

출처 및 근거

ORD 기록
ord-d8f7627c210f40e7aad1e77485a6808b
출처 데이터셋
uspto-grants-2013_12
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08618098B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트